Parathyroid cell growth in patients with advanced secondary hyperparathyroidism: Vitamin D receptor, calcium sensing receptor, and cell cycle regulating factors

Therapeutic Apheresis and Dialysis

Volumn 9, Issue SUPPL. 1, 2005, Pages

  Tokumoto, Masanori ^a   Taniguchi, Masatomo ^a   Matsuo, Dai ^a   Tsuruya, Kazuhiko ^a   Hirakata, Hideki ^a   Iida, Mitsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Calcium sensing receptor; Cyclin dependent kinase inhibitor; Hyperplasia; Secondary hyperparathyroidism; Vitamin D receptor

Indexed keywords

22 OXACALCITRIOL; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM SENSING RECEPTOR; CYCLIN DEPENDENT KINASE INHIBITOR; N [3 (2 CHLOROPHENYL)PROPYL] 1 (3 METHOXYPHENYL)ETHYLAMINE; PROTEIN P21; PROTEIN P27; RETINOID X RECEPTOR; VITAMIN D; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; CELL CYCLE PROTEIN;

AUTONOMIC NERVE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL GROWTH; CELL LABELING; CELL PROLIFERATION; CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; DOSE RESPONSE; DOWN REGULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PULSE THERAPY; EXTRACELLULAR CALCIUM; HUMAN; HYPERCALCEMIA; HYPERTHYROIDISM; KIDNEY TRANSPLANTATION; NICK END LABELING; NODULAR HYPERPLASIA; NONHUMAN; OBSERVATION; ORGAN SIZE; PARATHYROID CELL; PARATHYROID GLAND; PARATHYROID HYPERPLASIA; PATHOGENESIS; PATHOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; RECEPTOR DENSITY; REMISSION; SECONDARY HYPERPARATHYROIDISM; TREATMENT RESPONSE; CELL DIVISION; CYTOLOGY; DISEASE COURSE; PHYSIOLOGY; REVIEW;

CELL CYCLE PROTEINS; CELL DIVISION; DISEASE PROGRESSION; HUMANS; HYPERPARATHYROIDISM, SECONDARY; PARATHYROID GLANDS; RECEPTORS, CALCITRIOL; RECEPTORS, CALCIUM-SENSING;

EID: 33645248943     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2005.00302.x     Document Type: Conference Paper

References (70)

1. Malluche H, Faugere MC. Renal bone disease 1990: an unmet challenge for the nephrologist. [Review]. Kidney Int 1990;38:192-211.
2. Parfitt AM. Parathyroid growth. In: Bilezikian JP, Marcus R, Levine MA, eds. The Parathyroids Basic and Clinical Concepts, 2nd edn. San Diego, CA: Academic, 2001;293-329.
3. Llach F. Secondary hyperparathyroidism in renal failure: the trade-off hypothesis revisited. Am J Kidney Dis 1995;25:663-79.
4. Akizawa T, Fukagawa M, Koshikawa S, Kurokawa K. Recent progress in management of secondary hyperparathyroidism of chronic renal failure. [Review]. Curr Opin Nephrol Hypertens 1993;2:558-65.
5. Coburn JW, Llach F. Renal osteodystrophy. In: Narins RG, ed. Clinical Disorders of Fluid and Electrolyte Metabolism, 5th edn. New York: McGraw-Hill, 1994;1299-377.
6. Tokumoto M, Tsuruya K, Fukuda K et al. Reduced p21, 27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism. Kidney Int 2002;62:1196-207.
7. Tokumoto M, Taniguchi M, Matsuo D et al. Diminished cyclin-dependent kinase inhibitor (CDKI) as a main stream to parathyroid gland (PTG) hyperplasia linking with down-regulation of calcium sensing receptor (CaSR). J Am Soc Nephrol 2003;14:460A.
8. Tokumoto M, Taniguchi M, Matsuo D et al. Diminished expression of retinoid X receptor (RXR) -α links with the reduced expression of vitamin D receptor (VDR), p21, and p27 in the parathyroid (PT) glands of secondary hyperparathyroidism (2HPT) (Abstract). J Am Soc Nephrol 2004;15:34A.
9. Slatopolsky E, Weerts C, Thielan J et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy- cholecalciferol in uremic patients. J Clin Invest 1984;74:2136-43.
10. Fukagawa M, Kitaoka M, Yi H et al. Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron 1994;68:221-8.
11. Tominaga Y, Tanaka Y, Sato K et al. Recurrent renal hyperparathyoidism and DNA analysis of autografted parathyroid tissue. World J Surg 1992;16:595-603.
12. Tominaga Y, Takagi H. Histology, pathopysiology and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 1997;13:78-86.
13. Goodman WG, Veldhuis JD, Belin TR et al. Calcium-sensing by parathyroid glands in secondary hyperparathyroidism. J Clin Endocrinol Metab 1998;83:2765-72.
14. Haussler MR, Whitfield GK, Haussler CA et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 1998;13:325-49.
15. 3 receptor to positive and negative vitamin D response elements. Arch Biochem Biophys 1996;334:223-34.
16. Jones G, Strungnell SA, Deluca HF. Current understanding of the molecular actions of vitamin D. Physiol Rev 1998;78:1193-231.
17. 2, and D in bovine parathyroid and CaR-transfected, human embryonic kidney (HEK293) cells. J Bone Miner Res 1997;12:715-25.
18. Kifor O, MacLeod RJ, Diaz R et al. Regulation of MAP kinase by calcium- sensing receptor in bovine parathyroid and CaR-transfected HEK293 cells. Am J Physiol Renal Physiol 2001;280:F291-302.
19. Almaden Y, Canalejo A, Ballesteros E et al. Regulation of arachidonic acid production by intracellular calcium in parathyroid cells: effect of extracellular phosphate. J Am Soc Nephrol 2002;13:693-8.
20. Bourdeau A, Souberbielle JC, Bonnet P et al. Phospholipase-A2 action and arachidonic acid metabolism in calcium-mediated parathyroid hormone secretion. Endocrinology 1992;130:1339-44.
21. Canalejo A, Canadillas S, Ballesteros E et al. Importance of arachidonic acid as a mediator of parathyroid gland response. Kidney Int Suppl 2003;85:S10-13.
22. 3 in the parathyroid glands of patients with renal failure. N Engl J Med 1987;316:1573-7.
23. 3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993;92:1436-43.
24. Carling T, Rastad J, Szabo E et al. Reduced vitamin D receptor messenger ribonucleic acid levels in primary and secondary hyperparathyroidism. J Endocrinol Metab 2000;85:2000-3.
25. 3 receptors in experimental uremia. Kidney Int 1987;32:350-3.
26. 2D receptors are decreased in parathyroid glands from chronically uremic dogs. Kidney Int 1989;35:19-23.
27. 3 and 22-oxacalcitol prevent the decrease in vitamin D receptor content in the parathyroid glands of uremic rats. Kidney Int 1996;50:34-9.
28. Shiizaki K, Negi S, Hatamura I et al. Biochemical and cellular effects of direct maxacalcitol injection into parathyroid gland in uremic rats. J Am Soc Nephrol 2005;16:97-108.
29. Brown AJ, Ritter CS, Finch JL et al. Decreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats: role of dietary phosphate. Kidney Int 1999;55:1284-92.
30. Ritter CS, Finch JL, Slatopolsky EA et al. Parathyroid hyperplasia in uremic rats precedes down-regulation of the calcium receptor. Kidney Int 2001;60:1737-44.
31. 2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1996;81:1598-606.
32. Garrett JE, Steffey ME, Nemeth EF. The calcium receptor agonist NPS R-568 suppresses PTH mRNA levels in cultured bovine parathyroid cells (Abstract). J Bone Miner Res 1995;10:S387.
33. Wada M, Furuya Y, Sakiyama J et al. The calcimimetic compound NPS R-568 suppresses parathyroid proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 1997;100:2977-83.
34. Yano S, Sugimoto T, Tsukamoto T et al. Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism. Kidney Int 2000;58:1980-6.
35. Tominaga Y, Tsuzuki T, Uchida K et al. Expression of PRAD1/cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma. Kidney Int 1999;55:1375-83.
36. Tominaga Y, Grimelius L, Falkmer UG et al. DNA ploidy pattern of parathyroid parenchymal cells in renal secondary hyperparathyroidism. Anal Cell Pathol 1991;3:325-33.
37. Ohta K, Manabe T, Katagiri M et al. Expression of proliferative cell nuclear antigens in parathyroid glands of renal hyperparathyroidism. World J Surg 1994;18:625-9.
38. WAF1 and transforming growth factor-α mediate dietary phosphate regulation of parathyroid cell growth. Kidney Int 2001;59:855-65.
39. KIP1 mRNA levels in tumors of primary and secondary hyperparathyroidism. Clin Endocrinol 2004;60:389-93.
40. Fukagawa M, Okazaki R, Takano K et al. Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis. N Engl J Med 1990;323:421-2.
41. Kremer R, Bolivar I, Goltzman D et al. Influence of calcium and 1,25-dihydroxycholecalciferol on proliferation and protooncogene expression in primary cultures of bovine parathyroid cells. Endocrinology 1989;125:935-41.
42. 3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 1989;35:1049-56.
43. Koike T, Fukuda N, Fukagawa M et al. Correlation of enhanced cell proliferation with decreased density of vitamin D receptor in situ in parathyroid hyperplasia in chronic dialysis patients. Nephrology 1997;3:279-84.
44. 3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 1996;10:142-53.
45. Cozzolino M, Lu Y, Finch J et al. p21WAF1 and TGF-α mediate parathyroid growth arrest by vitamin D and high calcium. Kidney Int 2001;60:2109-17.
46. Naveh-Many T, Silver J. Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. J Clin Invest 1990;86:1313-19.
47. Wiese RJ, Uhland-Smith A, Ross TK et al. Up-regulation of the vitamin D receptor in response to 1,25-dihydroxyvitamin D3 results from ligand-induced stabilization. J Biol Chem 1992;267:20082-6.
48. Patel SR, Ke H-Q, Vanholder R et al. Inhibition of calcitriol receptor binding to vitamin D responsive elements by uremic toxins. J Clin Invest 1995;96:50-9.
49. Moallem E, Silver J, Kilav R et al. RNA protein binding and post transcriptional regulation of PTH gene expression by calcium and phosphate. J Biol Chem 1998;273:5253-9.
50. Svensson O, Wernerson A, Reinholt FP. Effect of calcium depletion on the rat parathyroids. Bone Miner 1998;3:259-69.
51. Wernerson A, Widholm SM, Svensson O et al. Parathyroid cell number and size in hypocalcemic young rats. APMIS 1991;99:1096-102.
52. Naveh-Many T, Rahamimov R, Livni N et al. Parathyroid cell proliferation in normal and chronic renal failure rats: the effects of calcium, phosphate and vitamin D. J Clin Invest 1995;96:1786-93.
53. Bianchi S, Fabiani S, Muratori M et al. Calcium modulates the cyclin D1 expression in a rat parathyroid cell line. Biochem Biophys Res Commun 1994;204:691-700.
54. Sakaguchi K. Acidic fibroblast growth factor autocrine system as a mediator of calcium-regulated parathyroid cell growth. J Biol Chem 1992;267:24554-62.
55. Sakaguchi K, Ikeda K, Curcio F et al. Subclones of a rat parathyroid cell line (PT-r): regulation of growth an production of parathyroid hormone-related peptide (PTHRP). J Bone Miner Res 1990;5:863-9.
56. Gogusev J, Duchambon P, Hory B et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997;51:328-36.
57. Chin J, Miller SC, Wada M et al. Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats. J Am Soc Nephrol 2000;11:903-11.
58. 2+-sensing receptor gene causes familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 1993;75:1297-303.
59. Bai M, Janicic N, Trivedi S et al. Markedly reduced activity of mutant calcium-sensing receptor with an inserted Alu element from a kindred with familial hypocalciuric hypercalcemia and neonetal severe hyperparathyroidism. J Clin Invest 1997;99:1917-25.
60. Pearce SH, Williamson C, Kifor O et al. A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N Engl J Med 1996;335:1115-22.
61. Ho C, Conner DA, Pollak MR et al. A mouse model of human familial hypocalciuric hypercalcemia and neonetal severe hyperparathyroidism. Nat Genet 1995;11:389-94.
62. Sela-Brown A, Russell J, Koszewski NJ et al. Calreticulin inhibits vitamin D's action on the PTH gene in vitro and may prevent vitamin D's effect in vivo in hypocalcemic rats. Mol Endocrinol 1998;12:1193-200.
63. Brown AJ, Zhong M, Finch J et al. Rat calcium-sensing receptor is regulated by vitamin D but not by calcium. Am J Physiol-Renal 1996;270:F454-60.
64. Canaff L, Hendy GN. Human calcium-sensing receptor gene. Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D. J Biol Chem 2002;277:30337-50.
65. Taniguchi M, Tokumoto M, Matsuo D et al. Molecular mechanism of the vitamin D-induced progression of parathyroid gland hyperplasia in uremic rats fed high phosphorus diet: restoration of the expressions of vitamin D receptor, calcium sensing receptor and p21 (Abstract). Nephrol Dial Transplant 2003;18:136.
66. Imanishi Y, Hosokawa Y, Yoshimoto K et al. Dual abnormalities in cell proliferation and hormone regulation caused by cyclin D1 in a murine model of hyperparathyroidism. J Clin Invest 2001;107:1093-102.
67. Quarles LD, Yohay DA, Carroll BA et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 1994;45:1710-21.
68. Henry HL, Taylor AN, Norman AW. Response of chick parathyroid glands to the vitamin D metabolite 1,25-cholecalciferol. J Nutr 1977;107:1918-26.
69. Taniguchi M, Tokumoto M, Matsuo D et al. Up-regulation of both Ca-sensing receptor (CaSR) and vitamin D receptor (VDR) in diffuse hyperplastic parathyroid glands after renal transplantayion (RTx) (Abstract). J Am Soc Nephrol 2004;15:276A.
70. Shiizaki K, Hatamura I, Negi S et al. Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia. Kidney Int 2003;64:992-1003.